If pancreatitis is suspected, the medicine should be discontinued
The combination is always evaluated by the physician based on health status and individual objectives
Based on Phase 2 clinical trial data published in the New England Journal of Medicine (2023), retatrutide shares a side-effect profile broadly consistent with other GLP-1 receptor agonist class medicines, though the addition of glucagon receptor agonism may introduce some distinct effects
Results Here we show that gene expression of GLP-1R in pancreas is associated with a reduced risk of overall ovarian cancer risk odds ratio ([OR] = 0.94, 95% confidence interval [CI] 0.89-1.00) and endometrioid ovarian cancer (ENOC
These next-generation formulations aim to overcome earlier limitations in oral bioavailability, offering comparable results without injections
Cross-sectional estimates reflected overall cumulative incidence, whereas survival analyses provided temporal information, and the two approaches were considered complementary